Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | KDM4B | O94953 | 1/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | EIF4E | P06730 | 2/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820529 | 0.88 | CYP19A1 (0.50) | CYP19A1SLC22A12EIF4ECYP17A1SMN1; SMN2 | |
| SCHEMBL3820024 | 0.86 | CYP19A1 (0.52) | CYP19A1KDM4BKDM5CKDM5BEIF4E | |
| SCHEMBL3821583 | 0.86 | SMN1; SMN2 (0.46) | CYP19A1EIF4ECYP17A1CCR6SMN1; SMN2 | |
| SCHEMBL3823584 | 0.86 | CYP19A1 (0.43) | CYP19A1EIF4ECYP17A1CCR6SMN1; SMN2 | |
| SCHEMBL30263313 | 0.85 | CYP19A1 (0.44) | CYP19A1KDM4BKDM5CKDM5BEIF4E | |
| SCHEMBL3823804 | 0.85 | CYP19A1 (0.50) | CYP19A1EIF4ETDP1CYP17A1MKNK1 | |
| SCHEMBL3821571 | 0.84 | PIM1 (0.54) | CYP19A1SLC22A12EIF4ESIRT3TDP1 | |
| SCHEMBL3822069 | 0.83 | CYP19A1 (0.54) | CYP19A1EIF4ETDP1CYP17A1PIM1 | |
| SCHEMBL3814181 | 0.82 | CDK5 (0.54) | AREIF4E | |
| SCHEMBL5733727 | 0.81 | SIRT3 (0.46) | CYP19A1EIF4ESIRT3TDP1C1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1348706-B1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-7067537-B2 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1348706-A1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | CYP17A1, CYP21A2, HSD17B1 | CYP19A1 10/4885KDM4B 1174/4885KDM5C 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.